Open-label Study of Dupilumab in Patients With Atopic Dermatitis
Completed · Phase 3
Conditions studied: Atopic Dermatitis
In brief
The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD). The secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment. Optional Sub-Study: The primary objective of the sub-study is to assess the safety of the new dupilumab drug product in adult patients with AD after switching from the current dupilumab drug product. The secondary objectives of the sub-study are to evaluate systemic exposure and immunogenicity of the new dupilumab drug product in adult patients with AD.
Key facts
- Study ID
- NCT01949311
- Run by
- Regeneron Pharmaceuticals
- People needed
- 2733
- Starts
- 2013-10-10
- Expected to finish
- 2022-06-27
- Last updated by the study team
- 2023-10-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Regeneron Study Site — Birmingham, Alabama, United States
- Regeneron Study Site 1 — Birmingham, Alabama, United States
- Regeneron Study Site 2 — Birmingham, Alabama, United States
- Regeneron Study Site 2 — Phoenix, Arizona, United States
- Regeneron Study Site 3 — Phoenix, Arizona, United States
- Regeneron Study Site 1 — Phoenix, Arizona, United States
- Regeneron Study Site — Fort Smith, Arkansas, United States
- Regeneron Study Site — Rogers, Arkansas, United States
- Regeneron Study Site — Bakersfield, California, United States
- Regeneron Study Site — Clovis, California, United States
- Regeneron Study Site — Costa Mesa, California, United States
- Regeneron Study Site — Encinitas, California, United States
- Regeneron Study Site — Fremont, California, United States
- Regeneron Study Site — Lomita, California, United States
- Regeneron Study Site — Long Beach, California, United States
- Regeneron Study Site 1 — Los Angeles, California, United States
- Regeneron Study Site 2 — Los Angeles, California, United States
- Regeneron Study Site — Los Angeles, California, United States
- Regeneron Study Site — Oceanside, California, United States
- Regeneron Study Site — Orange, California, United States
- Regeneron Study Site — Rolling Hills Estates, California, United States
- Regeneron Study Site — San Diego, California, United States
- Regeneron Study Site 1 — San Diego, California, United States
- Regeneron Study Site 2 — San Diego, California, United States
- Regeneron Study Site — Anniston, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.